Oral FPR2/ALX modulators tune myeloid cell activity to ameliorate mucosal inflammation in inflammatory bowel disease.

• Tác giả: Xi-Lin Ge, Guan-Yi Li, Jie Li, Lin-Yu Li, Yang Li, Yuan Li, Zhi-Ping Li, Shi Lin, Qiang Liu, Qing Liu, Guang-Fei Wang, Ming-Wei Wang, Xiao-Zhen Wang, Wei Wu, Jun Yan, Wen-Sheng Yang, Qing-Tong Zhou
• Ngôn ngữ: eng
• Ký hiệu phân loại: 133.594 Types or schools of astrology originating in or associated with a
• Thông tin xuất bản: United States : Acta pharmacologica Sinica , 2025
• Bộ sưu tập: NCBI
• ID: 696655

Tóm tắt

Current treatments of inflammatory bowel disease (IBD) largely depend on anti-inflammatory and immunosuppressive strategies with unacceptable efficacy and adverse events. Resolution or repair agents to treat IBD are not available but potential targets like formyl peptide receptor 2 (FPR2/ALX) may fill the gap. In this study we evaluated the therapeutic effects of two small molecule FPR2/ALX modulators (agonist Quin-C1 and antagonist Quin-C7) against IBD. We first analyzed the cryo-electron microscopy structure of the Quin-C1-FPR2 in complex with heterotrimeric G